• OUTLOOK ARENA
  • VIEWS ON NEWS
  • SEPTEMBER 6, 2001

Kopran: Uncertain Future

Kopran, promoted by Parijat Enterprise, is one of the integrated domestic pharmaceutical players. Its products Aten (cardiovascular), Vent (respiratory) and Smyle enjoy strong brand equity. The company is in the midst of business and financial restructuring. The company is trying to change the perception and business profile from that of a commodity bulk manufacturer and supplier to a formulations based company with an ability to create strong brands.

In the first phase of restructuring process the company hived off of its penicillin based bulk business into a separate company (KDL Biotech). In the second phase, the OTC business of privately owned Kopran Pharmaceuticals Ltd. was merged with Kopran Ltd. The company intends to focus on the OTC segment and so far the company's brand 'Smyle' has created strong brand equity.

As per recent reports, Kopran is in talks with several pharmaceutical companies for sale of its formulations business or its 'Aten' brand in the cardiovascular segment. This comes as a surprise as bulk of company’s revenues in the formulations business come from the ‘Aten' brand. This could be due to the fact that the financial situation of the company is precarious with high debt levels. The debt/equity ratio is already alarming at 1.2:1. The financial performance of the company is also fluctuating.

Kopran-Rising Interest Burden
Quarter Ended 30/9/0031/12/0031/3/0130/6/01
Sales (Rs. Mn.)529568607478
Operating Margin (%)20%20%12%25%
Interest Burden (Rs.Mn.)51528078
PBT (%)9%8%4%4%

At the current market price of Rs 40 the stock is trading at 7x its 1QFY02 earnings. In wake of the recent development regarding the proposed sale of its formulation business, the future business plan of the company remains uncertain. It is likely that the company would concentrate purely on the OTC segment where it will have to work hard to establish strong brands.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407